A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

NCT06745531 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperphosphatemia Patients on Hemodialysis

Interventions

DRUG: TS-172 20~60 mg/day
DRUG: Placebo

Sponsor

Taisho Pharmaceutical Co., Ltd.